Key result
NaKtide and antioxidant drugs demonstrate potential in reversing systemic inflammation and cytokine storms associated with obesity and COVID-19, which may prevent the development of heart failure.
Why the study?
Systemic inflammation and cytokine storm drive adverse outcomes in obese patients with COVID-19, leading to heart failure, highlighting the need to explore Na/K-ATPase-mediated ROS generation and potential antioxidant strategies.
This review highlights the mechanistic role of the Na/K-ATPase oxidant amplification loop in obesity and COVID-19, suggesting NaKtide as a potential therapeutic strategy to prevent systemic inflammation and heart failure.
No takes yet. Share an insight, caveat, or question.
NaKtide merits preclinical testing for cytokine-driven heart failure; leaves open clinical translation pending prospective trials.
Xie et al. (2020) conducted a review in Obesity, COVID-19, and Heart Failure. NaKtide was evaluated. NaKtide and antioxidant drugs demonstrate potential in reversing systemic inflammation and cytokine storms associated with obesity and COVID-19, which may prevent the development of heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: